Exclusive Online Content
Asahi Kasei Bioprocess & Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development
Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have recently announced a strategic partnership in the burgeoning field of oligonucleotide….
Arvinas Enters Transaction With Novartis, Including Global License Agreement for the Development & Commercialization of Androgen Receptor Protein Degrader
Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for patients with prostate cancer….
Century Therapeutics Strengthens Position in Autoimmune Disease With Strategic Pipeline Expansion Supported by $60-Million Private Placement & Acquisition of Clade Therapeutics
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile….
Silo Pharma Set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Silo Pharma, Inc. recently announced it has exercised its option to license Alzheimer’s disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement….
4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity
Long-Term Partnership Agreed with Beacon Therapeutics for Clinical and Commercial AAV Production….
Biora Therapeutics Announces New Patent Covering its BioJet Liquid Jet Delivery Technology
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract….
ProMed Pharma Acquires SpineThera Manufacturing Capabilities & Option to License Intellectual Property
ProMed Pharma LLC and SpineThera, Inc. recently announced ProMed Pharma has acquired SpineThera’s cGMP manufacturing operational assets. ProMed Pharma also obtained an option to….
Asahi Kasei Medical & AW Technologies Enter Exclusive Distribution Agreement for TrachFlush in Japan
AW Technologies and Asahi Kasei Medical have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush device. AW Technologies is currently in the….
Oruka Therapeutics & ARCA biopharma Announce Merger Agreement
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases….
Bora Pharmaceuticals Completes Acquisition of Upsher-Smith
Bora Pharmaceuticals Co. recently announced it has completed the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer and marketer based in….
EXCLUSIVE ONLINE CONTENT
Cellares & Bristol Myers Squibb Announce $380-M Worldwide Capacity Reservation & Supply Agreement
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across its IDMO Smart Factories in the US, EU, and Japan for Bristol Myers Squibb’s use ….
Neurolentech Signs Technology Access Partnership With Kaerus Bioscience
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes….
Palisade Bio Enters Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach
Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers….
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….